Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

Cheng, Lie; Loke, Lydia; Lim, Elaine; Pearce, Fiona; Aziz, Mohamed Ismail Abdul

doi:10.1080/14737167.2021.1880323

Cited by 14 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The safety of the therapy is also extremely high, with toxicities identical to the original regimen. This is a particularly important observation, given the pharmacoeconomic evaluations being conducted around the world and the search for opportunities to reduce the already exceedingly inflated cost of oncology treatment [39,40,41]. Our study results confirm that biosimilars used in oncology are not only safe and effective but also a less costly option of therapy [39,42].…”

Section: Discussionsupporting

confidence: 68%

Trastuzumab Biosimilar ABP 980 Plus Pertuzumab and Docetaxel in the Therapy of Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw

Miacz¹,

Jagiełło-Gruszfeld²,

Kunkiel³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Human epidermal growth factor receptor 2 (HER-2) overexpression can be found in 15-20% of breast cancers, and it strongly correlates with aggressive clinical behavior and adverse prognosis. The first-line treatment for HER-2 positive metastatic breast cancers is the combination of trastuzumab, pertuzumab, and taxane (PTH). ABP 980 is a biosimilar of the innovator trastuzumab and is characterized by highly comparable effectiveness. Methods: The group of 61 patients with HER-2 positive MBC received biosimilar ABP 980 plus pertuzumab and docetaxel from November, 18, 2018 to December, 24, 2019. The response to therapy, overall survival (OS), progression-free survival (PFS), metastases, and adverse effects among patients were determined and analyzed. Results: Initially, 42 women responded partially to the treatment and their median PFS was 27 months. Median PFS for the whole group was 18 months. Cardiotoxicity of treatment was noticed in all patients in the form of the reduction in left ventricular ejection fraction but only in 2 cases, it was the reason for withdrawing from therapy. Conclusion: Biosimilar ABP 980 is registered in the same indications as the innovator trastuzumab and their effectiveness, as well as side effects, are comparable. The costs of biosimilar make the therapy more accessible and thus more patients with MBC around the world can receive relevant treatment.

show abstract

Section: Discussionsupporting

confidence: 68%

Trastuzumab Biosimilar ABP 980 Plus Pertuzumab and Docetaxel in the Therapy of Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw

Miacz¹,

Jagiełło-Gruszfeld²,

Kunkiel³

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…In a recent study, Cheng et al [ 71 ] evaluated the cost-effectiveness of pertuzumab with biosimilar trastuzumab and docetaxel as initial treatment in patients with HER2+ MBC. They concluded that, although biosimilar trastuzumab reduced the cost of the pertuzumab combination regimen, the cost–benefit ratio remained high.…”

Section: Resultsmentioning

confidence: 99%

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Triantafyllidi

Triantafillidis

2022

Biomedicines

View full text Add to dashboard Cite

Trastuzumab is a monoclonal antibody used in the treatment of breast cancer in cases where the tumor overexpresses the HER2 receptor, a cell membrane receptor activated by the epidermal growth factor. Intravenous and subcutaneous administration of trastuzumab have comparable clinical and pharmacological characteristics, but trastuzumab biosimilars are currently only available in intravenous form. Trastuzumab biosimilars are ultimately preferred by a proportion of patients, especially in cases where co-administration of other chemotherapeutic agents, such as trastuzumab and tucatinib, a small molecule of tyrosine kinase inhibitor, is required in patients with HER-positive metastatic breast cancer. Oncologists should be well-aware of the advantages of intravenously administered trastuzumab biosimilars over subcutaneous administration, certainly also taking into account the patient’s preferences. Further cost-effectiveness analyses will be very important, along with expectations regarding successful concomitant subcutaneous administration of trastuzumab with other anticancer drugs, such as pertuzumab. This systematic review describes and analyzes the so-far published studies concerning the use of the available trastuzumab biosimilars in HER-positive early and metastatic breast cancer in terms of efficacy, safety, and cost–benefit ratio. An attempt was also made to draw some conclusions and to comment on future needs and perspectives.

show abstract

“…Our third scenario analysis showed that adding pertuzumab to the PTR or PTbiol combination regimen, which still showed a high ICER, is unlikely to be a cost-effective strategy for HER2 + MBC treatment in Taiwan. However, the combination of pertuzumab and trastuzumab biosimilar still provided a cost savings of approximately 5.2% over [40,41].…”

Section: Discussionmentioning

confidence: 99%

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer

et al. 2022

View full text Add to dashboard Cite

Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore

Cited by 14 publications

References 22 publications

Trastuzumab Biosimilar ABP 980 Plus Pertuzumab and Docetaxel in the Therapy of Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw

Trastuzumab Biosimilar ABP 980 Plus Pertuzumab and Docetaxel in the Therapy of Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw

Systematic Review on the Use of Biosimilars of Trastuzumab in HER2+ Breast Cancer

Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer

Contact Info

Product

Resources

About